Rebecca S Mchugh

US Patent:

20080221016, Sep 11, 2008

Filed:

Jan 31, 2008

Appl. No.:

12/023470

Inventors:

Michael Chapman Byrne - Brookline MA, US
Ethan Menahem Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca Suzanne McHugh - Auburn CA, US
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US

Assignee:

WYETH - Madison NJ
The Government USA, as respresented by the Secretary, Department of Health - Rockville MD

International Classification:

A61K 38/00
C12N 5/06
A61P 37/00

US Classification:

514 2, 435375

Abstract:

The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.

US Patent:

20030133936, Jul 17, 2003

Filed:

Jul 12, 2002

Appl. No.:

10/194754

Inventors:

Michael Byrne - Brookline MA, US
Ethan Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca McHugh - Silver Spring MD, US
Matthew Whitters - Hudson MA, US
Deborah Young - Melrose MA, US

International Classification:

A61K039/395
G01N033/567
A61K031/00

US Classification:

424/146100, 514/001000, 435/007210

Abstract:

The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.